Experimental analysis shows decr2 modulates tumor sensitivity to anti-pd-l1 therapy in vivo, indicating its relevance in immunotherapy.
Supplementary Figure S3. Decr2 modulates tumor sensitivity to anti-PD-L1 therapy in vivo.
No takes yet. Share an insight, caveat, or question.
Li et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: